Cancer Drug News Do certain diabetes drugs increase the risk of acute kidney injury in patients taking anti-cancer therapies?
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for adult relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r ALL)
Cancer Drug News Age-old malaria treatment found to improve nanoparticle delivery to tumours November 8, 2017 A new study shows that a 70-year-old malaria drug can block immune cells in the…
Breast Cancer Warfarin associated with lower risk of cancer incidence in over 50s November 8, 2017 Warfarin is a widely used anticoagulant prescribed to as many as 10 percent of adults…
Cancer Drug News How to train your drugs: nanotherapeutics October 31, 2017 Chemotherapy benefits a great many patients but the side effects can be brutal. When a…
Cancer Drug News Long-term aspirin use reduces the incidence of digestive cancers by up to 47 percent October 31, 2017 The long-term use of aspirin has been shown to significantly reduce the incidence of digestive…
Breast Cancer ‘Double decker’ antibody technology fights cancer October 31, 2017 Scientists from The Scripps Research Institute (TSRI) have created a new class of antibody-drug conjugates…
Cancer Drug News Tumour growth blocked by potato virus-chemo combo October 27, 2017 Researchers funded by the National Institute of Biomedical Imaging and Bioengineering combined the immune response…
Cancer Drug News Size and scope of “paradigm shift in cancer therapy” revealed October 17, 2017 Thousands of Australians who face imminent death from cancer could live longer if the use…
Cancer Drug News PBS listing makes lifesaving cancer drug affordable for sufferers October 11, 2017 Sean Parnell, The Australian Patients with leukemia and lymphoma will no longer have to pay…
Cancer Drug News No clear evidence that most new cancer drugs extend or improve life October 11, 2017 The majority of cancer drugs approved in Europe between 2009 and 2013 entered the market…
Melanoma and Skin Cancer ESMO 2017: Combination Targeted Adjuvant Therapy Doubles Relapse-free Survival in Stage III Melanoma September 12, 2017 Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage…